Aimmune Therapeutics
AIMT
AIMT was delisted on the 12th of October, 2020.
58 hedge funds and large institutions have $476M invested in Aimmune Therapeutics in 2015 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 28 increasing their positions, 7 reducing their positions, and 14 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 7
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
0% more funds holding
Funds holding: 58 → 58 (0)
0% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 14
14% less capital invested
Capital invested by funds: $551M → $476M (-$75.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$15.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.63M |
| 3 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$4.48M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$4.24M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$3.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$25.2M |
| 2 |
Jennison Associates
New York
|
-$5.08M |
| 3 |
FAM
Fred Alger Management
New York
|
-$2.42M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.85M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$1.73M |
AIMT Hedge Fund Activity: Q4 2015 in Review
58 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q4 2015, worth a combined $476M — down 14% from $551M a quarter earlier.
Fund positioning in AIMT was balanced in Q4 2015: 14 funds opened new positions, 14 closed out, 28 added to existing stakes and 7 trimmed.
The largest buyer was Eagle Asset Management, opening a new position worth an estimated $15.8M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $25.2M sold.
- 58 institutional investors held Aimmune Therapeutics (AIMT) as of Q4 2015, unchanged from Q3 2015.
- Funds reported $476M of Aimmune Therapeutics stock for Q4 2015, down 14% quarter-over-quarter.
- 14 funds opened new Aimmune Therapeutics positions in Q4 2015 and 14 closed out, a net change of 0 holders.
- The largest Aimmune Therapeutics buyer in Q4 2015 was Eagle Asset Management, an estimated $15.8M added.
- The largest Aimmune Therapeutics seller in Q4 2015 was PFM Health Sciences, an estimated $25.2M sold.
Based on aggregated 13F filings for Q4 2015.